


## Aucubin

Cat. No.:	HY-N0664		
CAS No.:	479-98-1		
Molecular Formula:	C <sub>15</sub> H <sub>22</sub> O <sub>9</sub>		
Molecular Weight:	346.33		
Target:	Bacterial		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 100 mg/mL (288.74 mM)  
 DMSO : 100 mg/mL (288.74 mM; Need ultrasonic)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.8874 mL	14.4371 mL	28.8742 mL
	5 mM	0.5775 mL	2.8874 mL	5.7748 mL
	10 mM	0.2887 mL	1.4437 mL	2.8874 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: 2.5 mg/mL (7.22 mM); Suspended solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

#### Description

Aucubin, an iridoid glucoside, is isolated from *Plantago asiatica*, *Eucommia ulmoides*, the leaves of *Aucuba japonica* and more recently from butterfly larva. Aucubin has many biological activities, such as antioxidant, anti-aging, anti-inflammatory, antimicrobial, anti-fibrotic, anti-cancer, hepatoprotective, neuroprotective and osteoprotective effects<sup>[1][2][3]</sup>.

<b>In Vitro</b>	<p>Aucubin (0.001-1 µg/mL; pretreated for 30 min) dose-dependently inhibits IgE-induced TNF-α and IL-6 production and expression in RBL-2H3 cells, with IC<sub>50</sub>s of 0.101 and 0.19 µg/mL, respectively<sup>[2]</sup>.</p> <p>Aucubin (0.01 µg/mL; pretreated for 30 min) inhibits IgE-induced nuclear translocation of p65 subunit of NF-κB and degradation of IκBα in RBL-2H3 cells<sup>[2]</sup>.</p> <p>Aucubin (0.001-1 mM; 12 h) increases PC12 cellular viability and markedly inhibits H<sub>2</sub>O<sub>2</sub>-induced apoptotic cell death<sup>[4]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
<b>In Vivo</b>	<p>Aucubin (5 mg/kg; i.p. for 15 d) has antioxidant and pancreas-protective effects on rats with streptozotocin-induced diabetes [1].</p> <p>Aucubin (40-200 mg/kg; a single i.p.) exhibits significant protective activity against α-amanitin intoxication in mice<sup>[5]</sup>.</p> <p>Aucubin (5 mg/kg/day; i.p. for 21 d) decreases the breathing frequency, increases the lung dynamic compliance, alleviates lung parenchymal fibrotic changes, and reduces the intrapulmonary collagen disposition and inflammatory injury of BLM-stimulated mice<sup>[6]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="347 625 1515 1037"> <tr> <td data-bbox="347 625 618 688">Animal Model:</td> <td data-bbox="618 625 1515 688">Male Wistar rats (200-230 g) induced diabetes by a injection of streptozotocin<sup>[1]</sup></td> </tr> <tr> <td data-bbox="347 688 618 751">Dosage:</td> <td data-bbox="618 688 1515 751">5 mg/kg</td> </tr> <tr> <td data-bbox="347 751 618 814">Administration:</td> <td data-bbox="618 751 1515 814">I.p. twice daily for the first 5 days, followed by single injections daily for the last 10 days</td> </tr> <tr> <td data-bbox="347 814 618 1037">Result:</td> <td data-bbox="618 814 1515 1037"> <p>Increased the body weight of streptozotocin-diabetic rats.</p> <p>Lowered the blood glucose level.</p> <p>Decreased the level of lipid peroxidation and increased the activities of antioxidant enzymes.</p> <p>Increased in insulin immunoreactivity and the number of immunoreactive β cells compared with untreated diabetic rats.</p> </td> </tr> </table>	Animal Model:	Male Wistar rats (200-230 g) induced diabetes by a injection of streptozotocin <sup>[1]</sup>	Dosage:	5 mg/kg	Administration:	I.p. twice daily for the first 5 days, followed by single injections daily for the last 10 days	Result:	<p>Increased the body weight of streptozotocin-diabetic rats.</p> <p>Lowered the blood glucose level.</p> <p>Decreased the level of lipid peroxidation and increased the activities of antioxidant enzymes.</p> <p>Increased in insulin immunoreactivity and the number of immunoreactive β cells compared with untreated diabetic rats.</p>
Animal Model:	Male Wistar rats (200-230 g) induced diabetes by a injection of streptozotocin <sup>[1]</sup>								
Dosage:	5 mg/kg								
Administration:	I.p. twice daily for the first 5 days, followed by single injections daily for the last 10 days								
Result:	<p>Increased the body weight of streptozotocin-diabetic rats.</p> <p>Lowered the blood glucose level.</p> <p>Decreased the level of lipid peroxidation and increased the activities of antioxidant enzymes.</p> <p>Increased in insulin immunoreactivity and the number of immunoreactive β cells compared with untreated diabetic rats.</p>								

## CUSTOMER VALIDATION

- Stem Cell Res Ther. 2022 Aug 19;13(1):424.
- Int Immunopharmacol. 2024 Mar 10;129:111648.
- Int Immunopharmacol. 2023 Dec 2;126:111312.
- Pharmaceuticals. 2023 Nov 1, 16(11), 1545.
- Research Square Preprint. 2021 Feb.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Jin I, et, al. Antioxidant and pancreas-protective effect of aucubin on rats with streptozotocin-induced diabetes. Eur J Pharmacol. 2008 Mar 17;582(1-3):162-7.
- [2]. Jeong HJ, et, al. Inhibition of TNF-alpha and IL-6 production by Aucubin through blockade of NF-kappaB activation RBL-2H3 mast cells. Cytokine. 2002 Jun 7;18(5):252-9.
- [3]. Zeng X, et, al. A review of the pharmacology and toxicology of aucubin. Fitoterapia. 2020 Jan;140:104443.
- [4]. Xue HY, et, al. Protective effects of aucubin on H<sub>2</sub>O<sub>2</sub>-induced apoptosis in PC12 cells. Phytother Res. 2012 Mar;26(3):369-74.
- [5]. Chang LM, et, al. Aucubin: potential antidote for alpha-amanitin poisoning. J Toxicol Clin Toxicol. 1984 Jul;22(1):77-85.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA